David J Mazzo Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David J Mazzo.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David J Mazzo. David J Mazzo is an Chief Executive Officer in Caladrius Biosciences, Inc. ($NBS) and a Director in AVANIR PHARMACEUTICALS, INC. ($AVNR) and a in EyePoint Pharmaceuticals, Inc. ($EYPT) and a Director in pSivida Corp. ($PSDV) and a Director in Neuralstem, Inc. ($CUR).
Address: 11388 SORRENTO VALLEY ROAD, SUTIE 200 SAN DIEGO 92121 CA
Companies in which David J Mazzo is an Insider
AVANIR PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of David J Mazzo: Director
Holdings: 7,435 shares
Latest Transaction: Feb 15 2006
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
CALADRIUS BIOSCIENCES, INC.
Industry: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
Position of David J Mazzo: Chief Executive Officer
Holdings: 333,653 shares
Latest Transaction: Jan 15 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
EyePoint Pharmaceuticals, Inc.
Industry: LABORATORY ANALYTICAL INSTRUMENTS [3826]
Position of David J Mazzo:
Holdings: 200,083 shares
Current Value: $332,138
Latest Transaction: Oct 11 2019
$EYPT Market Capitalization: $60.15M
$EYPT Previous Close: $1.66
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
PALISADE BIO, INC.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of David J Mazzo: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Apr 26 2021
$SNCA Market Capitalization: $28.01M
$SNCA Previous Close: $3.02
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of David J Mazzo
Sentiment: All, AVNR, NBS, EYPT, SNCA
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 26 2021 | SNCA | Seneca Biopharma, ... | Mazzo David J | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.56 | 5,936 | 9,260 | 299,505 | 305.4 K to 299.5 K (-1.94 %) |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.55 | 6,425 | 9,959 | 305,441 | 311.9 K to 305.4 K (-2.06 %) |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.55 | 21,787 | 33,770 | 311,866 | 333.7 K to 311.9 K (-6.53 %) |
| Jan 15 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Grant | A | 0.00 | 39,000 | 0 | 333,653 | 294.7 K to 333.7 K (+13.24 %) |
| Jan 12 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Option Exercise | A | 1.59 | 60,000 | 95,400 | 60,000 | |
| Jan 12 2021 | NBS | CALADRIUS BIOSCIEN ... | Mazzo David J | Chief Executive Off ... | Payment of Exercise | F | 1.59 | 16,621 | 26,427 | 294,653 | 311.3 K to 294.7 K (-5.34 %) |